Analysts think ADMA stock price could increase by 61%
Feb 12, 2025, 12:25 PM
12.88%
What does ADMA do
ADMA Biologics, headquartered in Ramsey, New Jersey, specializes in manufacturing FDA-approved plasma-derived biologics for immune deficiencies and infectious diseases, employing 624 staff. The company went public on October 17, 2013.
6 analysts think ADMA stock price will increase by 60.58%. The current median analyst target is $25.50 compared to a current stock price of $15.88. The lowest analysts target is $19.28 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
